

TEPROTUMUMAB RESTARTS CLINICAL DEVELOPMENT IN NEW INDICATION

Company Announcement

- **Teprotumumab (RG1507) to be investigated for new indication**
- **River Vision Development Corporation to conduct clinical development under a license from Roche**

Copenhagen, Denmark; June 11, 2013 – Genmab A/S (OMX: GEN) announced today that teprotumumab (RG1507), an antibody developed by Genmab under our collaboration with Roche, will restart clinical development in a Phase 2 study in patients with active thyroid eye disease. Clinical development will be conducted by River Vision Development Corporation, who licensed teprotumumab from Roche.

"In drug development, it's often possible to take what was learned about a product in its initial development and apply it to new indications. We are pleased that River Vision will resume clinical development of teprotumumab for the potential treatment of ophthalmic conditions," said Jan van de Winkel, Ph.D., Chief Executive Officer.

Under our collaboration with Roche, Genmab will receive milestones as well as royalty payments on successful products.

River Vision Development Corporation is a private company focused on ophthalmology.

Today's news does not affect Genmab's financial guidance for 2013.

About Teprotumumab

Teprotumumab is a fully human antibody that targets the Insulin-like Growth Factor-1 Receptor (IGF-1R) which is a well validated target. Teprotumumab was previously investigated in various cancer indications.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development. Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates. Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

TEPROTUMUMAB RESTARTS CLINICAL DEVELOPMENT IN NEW INDICATION

Genmab A/S and its subsidiaries own the following trademarks: Genmab[®]; the Y-shaped Genmab logo[®]; the DuoBody[™] logo; HuMax[®]; HuMax-CD20[®]; DuoBody[®]; HexaBody[™] and UniBody[®]. Arzerra[®] is a trademark of GlaxoSmithKline.